Back Hepatitis B Hepatitis B Topics HBV Disease Progression

EASL 2014: Prolonged Pegylated Interferon + Tenofovir Does Not Prevent Hepatitis Delta Relapse

Treating hepatitis B patients with hepatitis delta virus (HDV) coinfection using pegylated interferon plus tenofovir (Viread) for 96 weeks may reduce HDV viral load, but side effects are frequent and it did not significantly improve the likelihood of hepatitis B surface antigen (HBsAg) reduction, according to a report at the 49thEASL International Liver Congress last week in London.

 

alt

Read more:

EASL 2014: New Research Sheds Light on Liver Cancer Diagnosis, Staging, and Treatment

Dramatic regional differences in survival rates for people with hepatocellular carcinoma (HCC) are largely attributable to varying national policies regarding screening and treatment, according to study findings presented at the 49thEASL International Liver Congress last week in London. Related research showed that percutaneous radiofrequency ablation is effective for treating single liver cancer tumors.

alt

Read more:

ILCA 2013: High HBV Viral Load Raises Risk of Progression to Liver Cancer

Hepatitis B patients with high HBV DNA levels, indicating active viral replication, are more likely to experience progression of abnormal liver nodules to hepatocellular carcinoma, researchers reported at the 7th International Liver Cancer Association Annual Conference (ILCA 2013) last month in Washington, DC.

alt

Read more:

Increased Distance Reduces Likelihood of Liver Transplant

alt

Living and receiving health care further away from a transplant center was associated with lower chances of being wait-listed for or receiving a liver transplant, according to a study of U.S. veterans described in the March 26 edition of JAMA.

Read more:

ICAAC 2013: Liver Cancer Often Diagnosed Late with Poor Survival in People with HIV

Hepatocellular carcinoma (HCC) is frequently diagnosed at an advanced stage in HIV positive people with hepatitis B or C coinfection, contributing to a high mortality rate that has changed little in recent years, according to a report at the recent 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2013) in Denver.

alt

Read more:

Can Coffee Help Prevent Liver Fibrosis?

There is good evidence that coffee has a beneficial effect in people at risk for liver fibrosis and there are plausible biological mechanisms to explain why, according to an editorial in the January 27 advance online edition of Hepatology. However, the amount needed to see such an effect may be too high for many people to tolerate, they cautioned.

alt

Read more:

FDA Warns of Hepatitis B Reactivation Risk with Immune-suppressing Cancer Drugs

The U.S. Food and Drug Administration (FDA) announced this week that it has approved labeling changes for 2 monoclonal antibody cancer drugs, ofatumumab (Arzerra) and rituximab (Rituxan), adding a stronger "black box" warning that they may cause hepatitis B virus (HBV) reactivation.

alt

Read more: